Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Gorringe KL, Aleskandarany MA, Alkawaz A, Mittal K, Aneja R, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2019 Jun 7. doi: 10.1038/s41379-019-0286-9. [Epub ahead of print]

PMID:
31175327
2.

A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.

Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani A, Raafat S, Alsaleem M, Ogden A, Johnston SJ, Aleskandarany MA, Fujii T, Shirabe K, Caldas C, Ashankyty I, Dalton L, Ellis IO, Desmedt C, Green AR, Mongan NP, Rakha EA.

Br J Cancer. 2019 Jun;120(12):1129-1136. doi: 10.1038/s41416-019-0486-6. Epub 2019 May 22.

PMID:
31114020
3.

Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.

Kurozumi S, Joseph C, Raafat S, Sonbul S, Kariri Y, Alsaeed S, Pigera M, Alsaleem M, Nolan CC, Johnston SJ, Aleskandarany MA, Ogden A, Fujii T, Shirabe K, Martin SG, Alshankyty I, Mongan NP, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2019 Jul;176(1):63-73. doi: 10.1007/s10549-019-05216-w. Epub 2019 Apr 2.

PMID:
30941650
4.

Glutamate dehydrogenase (GLUD1) expression in breast cancer.

Craze ML, El-Ansari R, Aleskandarany MA, Cheng KW, Alfarsi L, Masisi B, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 Feb;174(1):79-91. doi: 10.1007/s10549-018-5060-z. Epub 2018 Nov 23.

PMID:
30470977
5.

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair.

Johnston SJ, Ahmad D, Aleskandarany MA, Kurozumi S, Nolan CC, Diez-Rodriguez M, Green AR, Rakha EA.

BMC Cancer. 2018 Oct 23;18(1):1027. doi: 10.1186/s12885-018-4924-2.

6.

Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.

Kurozumi S, Joseph C, Sonbul S, Aleskandarany MA, Pigera M, Alsaleem M, Alsaeed S, Kariri Y, Nolan CC, Diez-Rodriguez M, Johnston S, Mongan NP, Fujii T, Shirabe K, Martin SG, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2018 Nov;172(1):61-68. doi: 10.1007/s10549-018-4891-y. Epub 2018 Jul 28.

PMID:
30056565
7.

Impact of breast cancer grade discordance on prediction of outcome.

Rakha EA, Aleskandarany MA, Toss MS, Mongan NP, ElSayed ME, Green AR, Ellis IO, Dalton LW.

Histopathology. 2018 Dec;73(6):904-915. doi: 10.1111/his.13709. Epub 2018 Sep 19.

PMID:
29999192
8.

Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.

Sonbul SN, Aleskandarany MA, Kurozumi S, Joseph C, Toss MS, Diez-Rodriguez M, Nolan CC, Mukherjee A, Martin S, Caldas C, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2018 Nov;31(11):1675-1682. doi: 10.1038/s41379-018-0092-9. Epub 2018 Jun 28.

PMID:
29955149
9.

Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.

Althobiti M, Aleskandarany MA, Joseph C, Toss M, Mongan N, Diez-Rodriguez M, Nolan CC, Ashankyty I, Ellis IO, Green AR, Rakha EA.

Histopathology. 2018 Dec;73(6):887-896. doi: 10.1111/his.13695. Epub 2018 Oct 9.

PMID:
29947077
10.

Breast cancer intratumour heterogeneity: current status and clinical implications.

Joseph C, Papadaki A, Althobiti M, Alsaleem M, Aleskandarany MA, Rakha EA.

Histopathology. 2018 Nov;73(5):717-731. doi: 10.1111/his.13642. Epub 2018 Jul 8. Review.

PMID:
29722058
11.

Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.

Kurozumi S, Joseph C, Sonbul S, Gorringe KL, Pigera M, Aleskandarany MA, Diez-Rodriguez M, Nolan CC, Fujii T, Shirabe K, Kuwano H, Storr S, Martin SG, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2018 Aug;170(3):525-533. doi: 10.1007/s10549-018-4777-z. Epub 2018 Apr 9.

PMID:
29633055
12.

Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.

Joseph C, Macnamara O, Craze M, Russell R, Provenzano E, Nolan CC, Diez-Rodriguez M, Sonbul SN, Aleskandarany MA, Green AR, Rakha EA, Ellis IO, Mukherjee A.

Br J Cancer. 2018 Apr;118(8):1142-1151. doi: 10.1038/s41416-018-0041-x. Epub 2018 Mar 28.

13.

Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine.

Aleskandarany MA, Vandenberghe ME, Marchiò C, Ellis IO, Sapino A, Rakha EA.

Pathobiology. 2018;85(1-2):23-34. doi: 10.1159/000477851. Epub 2018 Feb 10. Review.

PMID:
29428954
14.

MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer.

Craze ML, Cheung H, Jewa N, Coimbra NDM, Soria D, El-Ansari R, Aleskandarany MA, Wai Cheng K, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Br J Cancer. 2018 Jan;118(2):258-265. doi: 10.1038/bjc.2017.387. Epub 2017 Nov 23.

15.

Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer.

Aleskandarany MA, Sonbul S, Surridge R, Mukherjee A, Caldas C, Diez-Rodriguez M, Ashankyty I, Albrahim KI, Elmouna AM, Aneja R, Martin SG, Ellis IO, Green AR, Rakha EA.

Br J Cancer. 2017 Oct 10;117(8):1176-1184. doi: 10.1038/bjc.2017.261. Epub 2017 Aug 22.

16.

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.

Klimov S, Rida PC, Aleskandarany MA, Green AR, Ellis IO, Janssen EA, Rakha EA, Aneja R.

Br J Cancer. 2017 Sep 5;117(6):826-834. doi: 10.1038/bjc.2017.224. Epub 2017 Jul 18.

17.

Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.

Muftah AA, Aleskandarany MA, Al-Kaabi MM, Sonbul SN, Diez-Rodriguez M, Nolan CC, Caldas C, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2017 Jul;164(2):341-348. doi: 10.1007/s10549-017-4270-0. Epub 2017 May 6.

18.

Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma.

Sonbul SN, Gorringe KL, Aleskandarany MA, Mukherjee A, Green AR, Ellis IO, Rakha EA.

J Pathol Clin Res. 2017 Mar 30;3(2):105-114. doi: 10.1002/cjp2.65. eCollection 2017 Apr.

19.

Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.

Miligy I, Mohan P, Gaber A, Aleskandarany MA, Nolan CC, Diez-Rodriguez M, Mukherjee A, Chapman C, Ellis IO, Green AR, Rakha EA.

Histopathology. 2017 Aug;71(2):258-268. doi: 10.1111/his.13217. Epub 2017 May 26.

PMID:
28326600
20.

Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells.

Mittal K, Choi DH, Ogden A, Donthamsetty S, Melton BD, Gupta MV, Pannu V, Cantuaria G, Varambally S, Reid MD, Jonsdottir K, Janssen EA, Aleskandarany MA, Ellis IO, Rakha EA, Rida PC, Aneja R.

Sci Rep. 2017 Mar 8;7:43984. doi: 10.1038/srep43984.

21.

Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.

Green AR, Aleskandarany MA, Ali R, Hodgson EG, Atabani S, De Souza K, Rakha EA, Ellis IO, Madhusudan S.

Cancer Immunol Res. 2017 Apr;5(4):292-299. doi: 10.1158/2326-6066.CIR-16-0195. Epub 2017 Mar 2.

22.

Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme.

Rakha EA, Ahmed MA, Aleskandarany MA, Hodi Z, Lee AH, Pinder SE, Ellis IO.

Histopathology. 2017 Mar;70(4):632-642. doi: 10.1111/his.13117. Epub 2016 Dec 28.

PMID:
28028831
23.

Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.

Arora A, Parvathaneni S, Aleskandarany MA, Agarwal D, Ali R, Abdel-Fatah T, Green AR, Ball GR, Rakha EA, Ellis IO, Sharma S, Madhusudan S.

Mol Cancer Ther. 2017 Jan;16(1):239-250. doi: 10.1158/1535-7163.MCT-16-0290. Epub 2016 Nov 11.

24.

Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.

Aleskandarany MA, Abduljabbar R, Ashankyty I, Elmouna A, Jerjees D, Ali S, Buluwela L, Diez-Rodriguez M, Caldas C, Green AR, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2016 Sep;159(2):215-27. doi: 10.1007/s10549-016-3934-5. Epub 2016 Aug 11.

25.

Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.

Alshareeda AT, Negm OH, Aleskandarany MA, Green AR, Nolan C, TigHhe PJ, Madhusudan S, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2016 Aug;159(1):41-53. doi: 10.1007/s10549-016-3915-8. Epub 2016 Jul 27.

PMID:
27464795
26.

Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer.

Aleskandarany MA, Green AR, Ashankyty I, Elmouna A, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2016 Jul;158(2):287-95. doi: 10.1007/s10549-016-3893-x. Epub 2016 Jul 5.

PMID:
27380874
27.

Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT-YB1-MDR1 Signaling Pathway.

Mo D, Fang H, Niu K, Liu J, Wu M, Li S, Zhu T, Aleskandarany MA, Arora A, Lobo DN, Madhusudan S, Balajee AS, Chi Z, Zhao Y.

Cancer Res. 2016 May 15;76(10):3057-66. doi: 10.1158/0008-5472.CAN-15-2361. Epub 2016 Mar 24.

28.

Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer.

Shamanna RA, Lu H, Croteau DL, Arora A, Agarwal D, Ball G, Aleskandarany MA, Ellis IO, Pommier Y, Madhusudan S, Bohr VA.

Oncotarget. 2016 Mar 22;7(12):13269-84. doi: 10.18632/oncotarget.7906.

29.

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.

Green AR, Aleskandarany MA, Agarwal D, Elsheikh S, Nolan CC, Diez-Rodriguez M, Macmillan RD, Ball GR, Caldas C, Madhusudan S, Ellis IO, Rakha EA.

Br J Cancer. 2016 Apr 12;114(8):917-28. doi: 10.1038/bjc.2016.46. Epub 2016 Mar 8.

30.

The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.

Aleskandarany MA, Agarwal D, Negm OH, Ball G, Elmouna A, Ashankyty I, Nuglozeh E, Fazaludeen MF, Diez-Rodriguez M, Nolan CC, Tighe PJ, Green AR, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2016 Feb;156(1):9-20. doi: 10.1007/s10549-016-3709-z. Epub 2016 Feb 23.

PMID:
26907764
31.

An approach to the diagnosis of spindle cell lesions of the breast.

Rakha EA, Aleskandarany MA, Lee AH, Ellis IO.

Histopathology. 2016 Jan;68(1):33-44. doi: 10.1111/his.12865. Review.

PMID:
26768028
32.

RECQL4 helicase has oncogenic potential in sporadic breast cancers.

Arora A, Agarwal D, Abdel-Fatah TM, Lu H, Croteau DL, Moseley P, Aleskandarany MA, Green AR, Ball G, Rakha EA, Chan SY, Ellis IO, Wang LL, Zhao Y, Balajee AS, Bohr VA, Madhusudan S.

J Pathol. 2016 Mar;238(4):495-501. doi: 10.1002/path.4681. Epub 2016 Feb 2.

33.

Clinical utility of reverse phase protein array for molecular classification of breast cancer.

Negm OH, Muftah AA, Aleskandarany MA, Hamed MR, Ahmad DA, Nolan CC, Diez-Rodriguez M, Tighe PJ, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2016 Jan;155(1):25-35. doi: 10.1007/s10549-015-3654-2. Epub 2015 Dec 9.

PMID:
26661092
34.

Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers.

Arora A, Abdel-Fatah TM, Agarwal D, Doherty R, Croteau DL, Moseley PM, Hameed K, Green A, Aleskandarany MA, Rakha EA, Patterson K, Ball G, Chan SY, Ellis IO, Bohr VA, Bryant HE, Madhusudan S.

Carcinogenesis. 2016 Jan;37(1):63-71. doi: 10.1093/carcin/bgv163. Epub 2015 Nov 19.

35.

Overexpression of Carbonic Anhydrase IX is a Dismal Prognostic Marker in Breast Carcinoma in Egyptian Patients.

Samaka RM, Abd El-Wahed MM, Al Sharaky DR, Shehata MA, Hegazy SE, Aleskandarany MA.

Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):405-13. doi: 10.1097/PAI.0000000000000208.

PMID:
26574633
36.

Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.

Alsubhi N, Middleton F, Abdel-Fatah TM, Stephens P, Doherty R, Arora A, Moseley PM, Chan SY, Aleskandarany MA, Green AR, Rakha EA, Ellis IO, Martin SG, Curtin NJ, Madhusudan S.

Mol Oncol. 2016 Feb;10(2):213-23. doi: 10.1016/j.molonc.2015.09.009. Epub 2015 Oct 3.

37.

Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer.

Aleskandarany MA, Sonbul SN, Mukherjee A, Rakha EA.

Pathobiology. 2015 Sep;82(3-4):113-23. doi: 10.1159/000433583. Epub 2015 Aug 31. Review.

38.

Pleomorphic adenoma-like tumour of the breast.

Rakha EA, Aleskandarany MA, Samaka RM, Hodi Z, Lee AH, Ellis IO.

Histopathology. 2016 Feb;68(3):405-10. doi: 10.1111/his.12757. Epub 2015 Jul 28.

PMID:
26096183
39.

Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification.

Aleskandarany MA, Soria D, Green AR, Nolan C, Diez-Rodriguez M, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2015 Jun;151(2):325-33. doi: 10.1007/s10549-015-3406-3. Epub 2015 May 8.

PMID:
25953687
40.

Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer.

Arora A, Abdel-Fatah TM, Agarwal D, Doherty R, Moseley PM, Aleskandarany MA, Green AR, Ball G, Alshareeda AT, Rakha EA, Chan SY, Ellis IO, Madhusudan S.

Mol Cancer Ther. 2015 Apr;14(4):1057-65. doi: 10.1158/1535-7163.MCT-14-0939. Epub 2015 Feb 11.

41.

The prognostic and predictive significance of PARP-1 in locally advanced breast cancer of Egyptian patients receiving neoadjuvant chemotherapy.

Aiad HA, Kandil MA, El-Tahmody MA, Abulkheir IL, Abulkasem FM, Elmansori AA, Aleskandarany MA.

Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):571-9. doi: 10.1097/PAI.0000000000000124.

PMID:
25611238
42.

Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study.

Aleskandarany MA, Negm OH, Green AR, Ahmed MA, Nolan CC, Tighe PJ, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2014 Jun;145(2):339-48. doi: 10.1007/s10549-014-2927-5. Epub 2014 Apr 26.

PMID:
24771047
43.

TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome.

Aleskandarany MA, Negm OH, Rakha EA, Ahmed MA, Nolan CC, Ball GR, Caldas C, Green AR, Tighe PJ, Ellis IO.

Breast Cancer Res Treat. 2012 Nov;136(2):419-27. doi: 10.1007/s10549-012-2249-4. Epub 2012 Oct 4.

PMID:
23053644
44.

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer.

Aleskandarany MA, Green AR, Benhasouna AA, Barros FF, Neal K, Reis-Filho JS, Ellis IO, Rakha EA.

Breast Cancer Res. 2012 Jan 6;14(1):R3.

45.

A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer.

Ahmed MA, Aleskandarany MA, Rakha EA, Moustafa RZ, Benhasouna A, Nolan C, Green AR, Ilyas M, Ellis IO.

Breast Cancer Res Treat. 2012 Jun;133(3):979-95. doi: 10.1007/s10549-011-1865-8. Epub 2011 Nov 27.

PMID:
22119938
46.

MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups.

Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR.

Breast Cancer Res Treat. 2011 Jun;127(3):591-9. doi: 10.1007/s10549-010-1028-3. Epub 2010 Jul 11.

PMID:
20623333
47.

Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.

Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Ellis IO, Green AR.

Breast Cancer Res Treat. 2011 Jun;127(2):407-16. doi: 10.1007/s10549-010-1012-y. Epub 2010 Jul 9.

PMID:
20617378
48.

Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer.

Aleskandarany MA, Green AR, Rakha EA, Mohammed RA, Elsheikh SE, Powe DG, Paish EC, Macmillan RD, Chan S, Ahmed SI, Ellis IO.

Int J Cancer. 2010 Apr 1;126(7):1761-9. doi: 10.1002/ijc.24860.

49.

PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.

Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Paish EC, Macmillan RD, Ellis IO, Green AR.

Breast Cancer Res Treat. 2010 Jul;122(1):45-53. doi: 10.1007/s10549-009-0508-9. Epub 2009 Aug 22.

PMID:
19701705
50.

Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.

Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO.

Clin Cancer Res. 2009 Apr 1;15(7):2302-10. doi: 10.1158/1078-0432.CCR-08-2132. Epub 2009 Mar 24.

Supplemental Content

Loading ...
Support Center